Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Acromegaly - Part 1: Diagnostic and Clinical Issues.
Endocr Metab Immune Disord Drug Targets
; 20(8): 1133-1143, 2020.
Article
in En
| MEDLINE
| ID: mdl-31985386
ABSTRACT
Acromegaly is a rare disease. Improvements in lifespan in these patients have recently been reported due to transsphenoidal surgery (TSS), advances in medical therapy, and strict criteria for defining disease remission. This document reports the opinions of a group of Italian experts who have gathered together their prolonged clinical experience in the diagnostic and therapeutic challenges of acromegaly patients. Both GH and IGF-I (only IGF-I in those treated with Pegvisomant) are needed in the diagnosis and follow-up. Comorbidities (cardio-cerebrovascular disease, sleep apnea, metabolic derangement, neoplasms, and bone/joint disease) should be specifically addressed. Any newly diagnosed patient should be referred to a multidisciplinary team experienced in the treatment of pituitary adenomas.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Societies, Medical
/
Acromegaly
/
Insulin-Like Growth Factor I
/
Practice Guidelines as Topic
/
Human Growth Hormone
/
Endocrinologists
Type of study:
Diagnostic_studies
/
Guideline
/
Risk_factors_studies
Limits:
Humans
Country/Region as subject:
Europa
Language:
En
Journal:
Endocr Metab Immune Disord Drug Targets
Year:
2020
Document type:
Article